Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736044 | 0.98 | HRH3 (0.43) | OXTRAVPR1AHRH3HRH1 | |
| SCHEMBL736163 | 0.91 | HRH3 (0.43) | OXTRAVPR1AHRH3HRH1 | |
| SCHEMBL737585 | 0.90 | HRH3 (0.42) | OXTRAVPR1APIK3CDPIK3CAHRH3 | |
| SCHEMBL737780 | 0.90 | CHRNB2 (0.41) | OXTRAVPR1APIK3CDPIK3CACHRM4 | |
| SCHEMBL736238 | 0.89 | ACACB (0.44) | HRH3HRH1 | |
| SCHEMBL736550 | 0.88 | HRH3 (0.43) | HRH3HRH1 | |
| SCHEMBL736589 | 0.88 | HRH3 (0.42) | HRH3HRH1 | |
| SCHEMBL735563 | 0.88 | HRH3 (0.42) | HRH3HRH1 | |
| SCHEMBL735700 | 0.87 | HRH3 (0.45) | HRH3HRH1 | |
| SCHEMBL736570 | 0.87 | HRH3 (0.40) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | claimed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | claimed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | claimed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | OXTR 334/4885AVPR1A 200/4885PIK3CD 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.